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Abstract
Several studies of survival in women with BRCA1 mutations have shown either reduced survival or
no difference compared to controls. Programmes for early detection and treatment of inherited
breast cancer, have failed to demonstrate a significant improvement in survival in BRCA1 mutation
carriers.
One hundred and sixty-seven women with disease-associated germline BRCA1 mutations and
breast cancer from 1980 to 2001 were identified. Tumour characteristics, treatment given and
survival were recorded. A control group comprising three hundred and four women matched for
age, time of diagnosis and stage were used to compare survival.
BRCA1 mutation carriers were found to have a poorer prognosis, which could be explained by
neither the mode of surgical treatment nor the use of adjuvant chemotherapy. BRCA1 mutation
carriers with node negative breast cancer had worse overall survival than controls.
Our findings confirm the serious prognosis of BRCA1-associated breast cancer even when
diagnosed at an early stage, and that type of treatment does not influence prognosis.
Background
BRCA1-associated breast cancers differ from sporadic
breast cancer with regard to prognostic markers. BRCA-
associated breast cancers are usually high grade, hormone
receptor- and HER-2 negative and often express topoi-
somerase IIa [1-4]. Studies of survival for BRCA1-associ-
ated breast cancer based on mutation analysis have come
to varying conclusions: None has reported better survival
rate, many have reported no differences [5-7]. Two case-
control studies of early stage breast cancer [8,9] and a
study with prospectively ascertained cancers [10] failed to
show any survival disadvantage. However, a number of
studies have reported worse prognosis [11-19].
A study on the effects of interventions to prevent inherited
breast cancer in prospectively ascertained breast cancers in
screened women at family history clinics, indicated that
BRCA1 mutation carriers have less effect of early diagnosis
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improved early diagnosis by means of annual breast mag-
netic resonance imaging (MRI) in addition to annual
mammography, which has been shown to improve early
diagnosis [21], may not be accompanied by an improved
survival rate.
In the present study, we compared survival in BRCA1
mutation carriers with mode of treatment. Also, we com-
pared survival in BRCA1 mutation carriers with a control
group with sporadic breast cancer matched for age, stage
and time of diagnosis.
Materials and methods
All women found to be BRCA1 mutation carriers and
diagnosed with breast cancer in the years 1980 to 2001
were identified in the archives of Section for Inherited
Cancer, Department of Medical Genetics, Rikshospitalet-
Radiumhospitalet Medical Center, Oslo and Centre of
Medical Genetics and Molecular Medicine, Haukeland
University Hospital, Bergen. These two registers contain
about 95% of known BRCA1 mutation carriers in Norway.
All participating patients had given their consent during
genetic counselling. Permission from the Norwegian Data
Inspectorate had been given to gather the data from these
two archives and analyze them for scientific purposes.
Index patients and obligate carriers are included.
From 1980 treatment of breast cancer in Norway was
influenced by the guidelines from the Norwegian Breast
Cancer Group (NBCG) and was rather homogenous in
the whole country. For this reason we chose not to go fur-
ther back than 1980. Also, stage at diagnosis was consid-
ered less accurate before 1980.
The control group was found in the Norwegian Cancer
Registry matched for age, (+/- one year), time of diagnosis
(+/- one year) and stage. It was not always possible to find
two controls within the matching criteria. One hundred
and forty-five cases have two controls, 14 cases have one
control and eight have none.
For mutation carriers data on surgical treatment, his-
topathological findings, treatment given and the course of
the disease were extracted from the archives of the depart-
ments of genetics. Any missing information was retrieved
from hospital records. Due to limited resources and the
retrospective collection of data, no histopathological
review was done, all information was based on the origi-
nal report given at the time of diagnosis. Interpretation of
immunohistochemical staining for estrogen receptor (ER)
varied from centre to centre. In most cases, histopatholog-
ical grading, according to Bloom and Richardson [22],
modified by Elston and Ellis [23], was done. However,
grading had not been done in fifty-three (31.7%) cases.
ER status and histopathological grading were not availa-
ble for the controls. Because presence of a BRCA1 muta-
tion is strongly associated with absence of ER receptor and
high grade, selection of controls by these parameters
would have implied an element of informative censoring
– selecting controls by parameters associated with the
selection criterion for the cases.
Survival of mutation carriers was calculated inside the
electronical medical files. Survival in controls was calcu-
lated inside the electronical files of the Cancer Registry of
Norway. To compare survival from the different series,
pseudonymized data were exported and no research regis-
try was erected. All data collected were derived from stand-
ard health care procedures, no patient was examined, no
sample was obtained, and no specimen was re-examined
for this study.
Statistics
The survival analyses were performed using the Kaplan-
Meier model in SPSS version 14.0 (SPSS Inc., Chicago, IL,
USA). Death was scored as event. For calculation of con-
tralateral cancer incidence, patients were censored at con-
tralateral prophylactic mastectomy and contralateral
reduction operation. Patients were censored at oophorec-
tomy when considering ovarian cancer.
Results
A number of findings in the mutation carriers are detailed in
Table 1: Mean age at diagnosis was 44.4 years, median age
43.7, minimum age 27, maximum age 73. Of the 167 cases,
104 (62%) had stage 1 (T1-2N0) disease. They had predom-
inantly ductal cancers (82%). Fifty per cent and 43% had
tumour size T1 and T2, respectively, 49% were histopatho-
logical grade III, 52% were ER negative, and 61% were with-
out nodal spread. The incidence of local recurrence among
carriers operated with breast-conserving therapy (BCT) was
8/40 (20%). Median time to recurrence was 85 months,
minimum 29, and maximum 122 months. Bilateral prophy-
lactic salpingo-oophorectomy (BPSO) had been performed
in 104/167 (62.3%). Occult ovarian cancer was found in 8/
104 (8%) of those who had BPSO. Thirty-four (34/167
(20.4%)) had an oophorectomy due to suspicion of malig-
nancy. Details of the control population are given in table 2.
No association with survival for mastectomy compared to
BCT was found in survival analyses of all cases or, indeed,
when stage 1 was analyzed separately. Figure 1 illustrates
the latter in premenopausal cases. Likewise, there was no
obvious difference between survival of those having
received and those not having received chemotherapy,
neither in the total study population nor when stage 1 was
analyzed separately (Figure 2). Contralateral cancer was
seen in 42/154 (27%). Thirteen had previously under-
gone contralateral prophylactic mastectomy.Page 2 of 6
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years. Median follow-up time for carriers and controls
together was 10.2 years. Survival analyses of cases com-
pared to controls showed better survival of the cases ini-
tially, but later the opposite (Figure 3). A closer look at
specific cause of death showed that deaths from ovarian
cancer may have contributed to the shape of the survival
curve for the carriers. Considering survival of cases com-
pared to controls for stage 1 only, the initial better survival
among cases gradually disappeared, and the curves
Table 1: Characteristics of the 167 BRCA1 mutation carriers
no(%)
Age <30 6(3.6)
30–39 47(28.1)
40–49 70(41.9)
50–59 33(19.8)
60–69 7(4.2)
>/= 70 4(2.4)
Type of operation Mastectomy 125(74.9)
BCT 40(24.0)
Ablatio simplex 1(0.6)
Halsteds 1(0.6)
Stage 1(T1-2N0) 104(62.3)
2(T1-2N1) 54(32.3)
3(T1-2N2-3, T3-4N0-3) 9(5.4)
Size T1(tumour ≤2 cm) 83(49.7)
T2(tumour >2 cm, ≤5 cm 71(42.5)
T3(tumour >5 cm) 6(3.6)
T4(Infiltration in skin or muscle, inflammatory) 3(1.8)
Unknown 4(2.4)
Grade I 2(1.2)
II 21(12.6)
III 82(49.1)
Unknown, incl. DCIS, LCIS 62(37.1)
Nodal status Negative 101(60.5)
Positive 66(39.5)
ER status Negative 86(51.5)
Positive 45(26.9)
Unknown 36(21.6)
Type Ductal 137(82.0)
Medullary 11(6.6)
Lobular 5(3.0)
DCIS 6(3.6)
LCIS 3(1.8)
Anaplastic 1(0.6)
Tubular 1(0.6)
Mucinous 1(0.6)
Mixed ductal/lobular 1(0.6)
Mixed medullary/ductal 1(0.6)
Chemotherapy Yes 93(55.7)
No 74(44.3)
Contralateral cancer Yes 42(25.1)
No 110(65.9)
Prophylactic mastectomy contralat 13(7.8)
Reduction contralat 2(1.2)Page 3 of 6
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ure 4). Should significance testing be applied to such
curves, the p value would be 0.02.
Discussion
The results of this study confirm that early diagnosis and
treatment did not imply a general favourable prognosis in
the BRCA1 mutation carriers. This is compatible with the
prospective series of cancer cases with early diagnosis. [24].
On the other hand, in the prospective series the prognosis
of other groups of breast cancers was favourable. It is possi-
ble that some forms of familial or inherited breast cancers
are biologically different from both the cases and controls
in the current study. Furthermore, early diagnosis and treat-
ment may confer a favourable prognosis in the other
groups, but not in BRCA1 mutation carriers.
The majority of cases was premenopausal and had stage 1
disease. The results did not indicate that mastectomy was
superior to breast conserving surgery with respect to sur-
vival, neither in the total group nor in the stage 1 cancers
when considered separately. Similarly, there was no obvi-
ous effect of chemotherapy. Removing the cases that
received initial short-time chemotherapy from the series
had no effect on the results (data not shown). However,
before concluding that chemotherapy does not improve
Table 2: Age and stage for the 304 controls
no(%)
Age <30 11(3.6)
30–39 81(26.6)
40–49 134(44.2
50–59 56(18.4)
60–69 16(5.3)
>/= 70 6(2.0)
Stage 1(T1-2N0) 204(67.1)
2(T1-2N1) 91(29.9)
3(T1-2N2-3, T3-4N0-3) 9(3.0)
Overall survival in cases stage 1, age ≤55 years, stratified on typ  of operationFigure 1
Overall survival in cases stage 1, age ≤55 years, strat-
ified on type of operation. Initial numbers in groups are 
indicated in the figure. Halsteds operation orange line. 
Breastconserving operation: red line. Mastectomy: blue line.
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Overall survival in cases and controls. Initial numbers in 
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that this statement refers to a study on effect of standard
adjuvant chemotherapy as given some years ago. The
results may not have bearings on recent discussions on the
effect of cisplatin [25,26]. The conclusions were, however,
that none of the treatment options employed was associ-
ated with, or could explain, the serious prognosis in the
BRCA1 mutation carriers even in early stage disease at
time of diagnosis.
The first impression of the survival of cases compared to
controls was confusing, due to the initial better survival in
the BRCA1 mutation carriers and the later worse survival
resulting in overlapping curves. If our findings are repre-
sentative, they may explain some of the contradictions in
the literature: Survival compared to controls may differ
depending on the number of years of follow-up. We see a
number of factors that may possibly contribute to the
observed results. Mutation carrying families may have had
increased breast awareness and sought early diagnosis
(lead-time bias). In the nineteen-nineties several of the
mutation carriers had been enrolled into surveillance pro-
grams which could also contribute to lead-time bias. Use
of new chemotherapy may have increased survival in the
controls during the study period. The cases contracted
both contralateral cancers and ovarian cancers, all expres-
sions of the same underlying genetic defect. Censoring out
other expressions of the same genetic defect, is, however,
informative censoring if the question is prognosis in a
BRCA1 mutation carrier (which may not be identical to
prognosis of the first tumour detected). In short, the
results were indicative of multiple determining factors
which again may explain the fact that different studies
have arrived at different conclusions. With respect to dif-
ferent results in other reports, variations in population
structures may also have been instrumental.
Considering stage 1 tumours separately, the picture was
simpler: The crossing of the curves almost disappeared
and a difference between cases and controls became visi-
ble (Figure 4)
Comparing the present results with the survival following
early diagnosis and treatment of inherited breast cancer
[24]; both similarities and differences are obvious: The
survival of BRCA1-associated breast cancer seems close to
identical in the retrospective and prospective series –
meaning that the effect of early diagnosis and treatment
may have been negligible. In contrast, the other groups in
the prospective series (familial breast cancer without
demonstrable mutations and BRCA2 mutation carriers)
do well – and there is no initial crossing of the curves. The
latter observation strengthens the theory that methodo-
logical problems in the present retrospective series may be
associated with the crossing of the curves.
Whatever interpretation one may choose, the findings
were that stage 1 breast cancer in BRCA1 carriers has a
poor prognosis. These findings are supported by Rennert
et al [27] who found that the outcome was worse for
BRCA1 mutation carriers with small node-negative
tumours. This is worrisome, because it is adds to the rea-
sons for questioning the effect of our programme for early
detection and treatment to cure inherited breast cancer
[20,21,24], On the other hand, the suggestion of prophy-
lactic mastectomy in young ages – without having proof
that it is necessary – is problematic as well. It might be
wise to see prospective data on the effect of early diagnosis
of breast MRI with respect to survival, before we arrive at
firm conclusions and advise all mutation carriers to
choose prophylactic mastectomy.
We undertook the present study because the problems
discussed are serious and unsolved. We did arrive at the
two main conclusions we had expected: The confusion
apparent in the litterature may be explained by the fact
that the data are confusing. There may be nothing essen-
tially wrong with the results of the present study or any of
the previous conflicting reports. The most probable expla-
nation for the diversity of results is that there are several
factors with varying influence on the combined results.
The main conclusions in our study, are that BRCA1 asso-
ciated breast cancer has a serious prognosis, and this is
especially so for early stages. It questions the current belief
that early diagnosis will significantly improve survival in
BRCA1 mutation carriers.
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